from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. A drug, that inhibits ubiquitination, used for the treatment of multiple myeloma


Sorry, no etymologies found.


  • Onyx Pharmaceuticals jumped 4.54, or 21%, to 26.04, after reporting that its experimental drug, called carfilzomib, was effective in treating advanced multiple myeloma, a fatal blood cancer, in patients that had no remaining treatment options.

    Sterling Leads Bank Stocks; Cal-Maine Hatches 12% Rise

  • Onyx, which is developing a drug called carfilzomib to treat blood cancer, jumped this week by the most since July 2010 after two people with knowledge of the matter said the drugmaker is exploring options including a sale. -- Top News

  • Dr. Kauffman, in addition to partnering with Dr. Love across the company's portfolio, will continue to play a lead role in the clinical development of Onyx's pipeline of next-generation proteasome inhibitors, including carfilzomib, which is currently in a Phase 2b trial for relapsed, refractory multiple myeloma. News Articles

  • Onyx will pay $276 million upfront for the privately held South San Francisco, Calif. -based company, and in the process it gains Proteolix's cancer drug candidate carfilzomib, which is being tested as a treatment for multiple myeloma, non-Hodgkin lymphoma, and solid tumors.

    WTOP / Business / Biz Stories

  • Emeryville-based Onyx (NASDAQ: ONXX) said it may pay up to $575 million more in milestone payments depending on regulatory and development progress made on South San Francisco-based Proteolix's experimental drug, carfilzomib, which is being tested as a treatment for multiple myeloma.

    Dallas Business News - Local Dallas News | Dallas Business Journal

  • Some of the most exciting presentations for the future treatment of myeloma are the results of studies of new drugs such as carfilzomib and pomalidomide as single agents or with steroids, combinations that include existing drugs such as VELCADE plus vorinostat, or combinations now using REVLIMID with vorinostat.

    Health News from Medical News Today

  • Ligand partner Onyx Pharmaceuticals presented several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 16th Congress of the European Hematology Association EHA Annual Meeting in London.

  • We believe that the approval of carfilzomib would be a major positive for Onyx Pharma, which currently has just one marketed product, Nexavar cancer, in its portfolio.

  • CELG Revlimid and low dose dexamethasone with or without carfilzomib in relapsed multiple myeloma patients.

  • The company is seeking approval of carfilzomib as a treatment for patients with relapsed and refractory multiple myeloma.


Log in or sign up to get involved in the conversation. It's quick and easy.